培生 PSO 深 滬
等待開盤 11-04 09:30:00 美东时间
17.13
-0.180
-1.04%
華盛通- 最 高17.225
- 今 開17.16
- 成交量 76.67万股
- 最 低 16.98
- 昨 收 17.31
- 總市值 102.96亿
- 52周最高 18.43
- 市盈率 靜 25.62
- 換手率 0.13%
- 52周最低 11.6734
- 委 比 -75.36%
- 總股本 6.01亿
- 歷史最高 18.4746
- 量 比 0.82
- 振 幅 1.42%
- 歷史最低 3.1918
- 每 手 1
- 風險率 1.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pearson Reports Artisan Partners’ Voting Stake Fell to 11.998%
An update from Pearson ( ($PSO) ) is now available. Pearson plc is a global edu...
今天 00:47
培生收跌0.35%，成交额2433.22万美元
11月3日，培生（PSO）收跌0.35%，报17.31美元，成交额2433.22万美元，市值104.06亿美元。 行情数据 • 开盘价：17.45美元 • 最高...
11-03 05:53
Pearson Reports 601.8 Million Shares Outstanding at October-End
An update from Pearson ( ($PSO) ) is now available. Pearson plc is a London-bas...
11-02 21:44
Pearson Issues 21,379 Shares Under Employee Savings Plan
Pearson ( ($PSO) ) has provided an announcement. On 2 November 2026, Pearson pl...
11-02 21:44
Immutep Quarterly Activities Report Q1 FY27
Immutep focuses on advancing efti for HNSCC (CPS <1) and neoadjuvant STS, with trials targeting H2 CY27. IMP761, an anti-LAG-3 antibody for autoimmune diseases, is now a co-priority and will be featured at ACR 2026. The root cause analysis of TACTI-004 identified structural differences in efti manufacturing scales, leading to a new 200 L scale production. The company received A$0.86 million from Australia’s R&D Tax Incentive and €1.36 million fro...
10-29 12:00
Immutep Receives A$2.16 million French R&D Tax Incentive
Immutep Limited received a €1.36 million cash payment from the French Government under its CIR research tax incentive program for eligible R&D activities in 2025. This follows an A$0.86 million rebate from Australia and eligibility for Germany’s R&D tax incentive. The non-dilutive funding will support R&D for eftilagimod alfa (efti) and IMP761. Immutep’s cash reach extends into the first half of 2028.
10-28 12:00
培生收跌0.82%，成交额997.99万美元
10月24日，培生（PSO）收跌0.82%，报18.24美元，成交额997.99万美元，市值109.65亿美元。 行情数据 • 开盘价：18.24美元 • 最高...
10-24 04:53
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
Immutep Limited will present late-breaking data from the Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, at the ACR Convergence 2026. The study, conducted in healthy volunteers using CHDR’s KLH challenge model, aims to assess IMP761’s immunosuppressive effects. First interim results were presented at EULAR 2026. The poster, titled "IMP761, a Novel Immunosuppressive LAG-3 Agonist Antibody in the Clinic," will be available on Immu...
10-19 12:00
培生收涨2.13%，成交额2335.32万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 04:53
Stride to Appoint Steven Guttentag and Dylan Haggart to Board of Directors and Form Capital Allocation Committee
Stride, Inc. and Fivespan Partners have entered a cooperation agreement, with Dylan Haggart and Steven Guttentag joining Stride’s Board of Directors. The Board is forming a Capital Allocation Committee to evaluate the company’s capital structure and priorities, aiming to announce a target capital structure and cash flow framework within three months. Both new directors bring significant expertise, with Guttentag’s extensive experience in educatio...
10-09 12:00
